US trial for anti-infective catheters:
This article was originally published in Clinica
Implemed is to begin a US clinical trial of its Oligon antimicrobial polymer-coated urinary catheters after receiving an investigational device exemption from the FDA. Researchers will assess how well the Oligon technology reduces device-associated infections that frequently occur in the large bore catheters used in the urinary tract. The technology is based on oligodynamic iontopheresis, whereby silver ions are released to destroy microbes on the surface of a device. The multicentre trial will involve over 600 patients and be completed by the end of the year, said the Watertown, Massachusetts-based company.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.